阿西维辛用于难治性儿童实体瘤的I期研究。一项儿科肿瘤学组的研究。
A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.
作者信息
Baruchel S, Bernstein M, Whitehead V M, Devine S, Bell B, Dubowy R, Grier H, Kretschmar C, Langevin A M, Vietti T
机构信息
McGill University, Montreal, Canada.
出版信息
Invest New Drugs. 1995;13(3):211-6. doi: 10.1007/BF00873802.
Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.
42例进展期实体瘤和脑肿瘤患者进入了这项关于谷氨酰胺拮抗剂阿西维辛的I期研究，该药物通过静脉注射，每天给药30分钟，持续5天。观察到的主要毒性为骨髓抑制和中枢神经系统毒性（噩梦和嗜睡）。按照这个给药方案，最大耐受剂量为每天26mg/M²，持续5天。6例患者病情稳定，其中包括3例脑肿瘤患者。
Zotero 插件